» Articles » PMID: 34870090

Comprehensive Literature Review on COVID-19 Vaccines and Role of SARS-CoV-2 Variants in the Pandemic

Overview
Publisher Sage Publications
Date 2021 Dec 6
PMID 34870090
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Since the outbreak of the COVID-19 pandemic, there has been a rapid expansion in vaccine research focusing on exploiting the novel discoveries on the pathophysiology, genomics, and molecular biology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although the current preventive measures are primarily socially distancing by maintaining a 1 m distance, it is supplemented using facial masks and other personal hygiene measures. However, the induction of vaccines as primary prevention is crucial to eradicating the disease to attempt restoration to normalcy. This literature review aims to describe the physiology of the vaccines and how the spike protein is used as a target to elicit an antibody-dependent immune response in humans. Furthermore, the overview, dosing strategies, efficacy, and side effects will be discussed for the notable vaccines: BioNTech/Pfizer, Moderna, AstraZeneca, Janssen, Gamaleya, and SinoVac. In addition, the development of other prominent COVID-19 vaccines will be highlighted alongside the sustainability of the vaccine-mediated immune response and current contraindications. As the research is rapidly expanding, we have looked at the association between pregnancy and COVID-19 vaccinations, in addition to the current reviews on the mixing of vaccines. Finally, the prominent emerging variants of concern are described, and the efficacy of the notable vaccines toward these variants has been summarized.

Citing Articles

Prevalence and pattern of adverse events following COVID-19 vaccination among adult population in Sokoto metropolis, northwest, Nigeria.

Adamu H, Lawal S, Bawa I, Sani A, Adamu A PLoS One. 2025; 20(3):e0277585.

PMID: 40073304 PMC: 11903040. DOI: 10.1371/journal.pone.0277585.


A SARS-CoV-2 vaccine on an NIR-II/SWIR emitting nanoparticle platform.

Jiang Y, Sanyal M, Hussein N, Baghdasaryan A, Zhang M, Wang F Sci Adv. 2025; 11(6):eadp5539.

PMID: 39919189 PMC: 11804919. DOI: 10.1126/sciadv.adp5539.


An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.

Mambelli F, de Araujo A, Farias J, de Andrade K, Ferreira L, Minoprio P Pathogens. 2025; 14(1).

PMID: 39860984 PMC: 11768231. DOI: 10.3390/pathogens14010023.


Characteristics of health care workers with SARS-CoV-2 at a COVID-19 hospital in Türkiye: Homologous versus heterologous vaccination.

Aliravci I, Ertekin Y, Can G, Alkan S Pak J Med Sci. 2024; 40(8):1702-1708.

PMID: 39281253 PMC: 11395381. DOI: 10.12669/pjms.40.8.8455.


Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections.

Hurwitz S, De R, LeCher J, Downs-Bowen J, Goh S, Zandi K Viruses. 2024; 16(4).

PMID: 38675992 PMC: 11053489. DOI: 10.3390/v16040651.


References
1.
Lai M . Coronavirus: organization, replication and expression of genome. Annu Rev Microbiol. 1990; 44:303-33. DOI: 10.1146/annurev.mi.44.100190.001511. View

2.
Adhikari E, Moreno W, Zofkie A, MacDonald L, Mcintire D, Collins R . Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Netw Open. 2020; 3(11):e2029256. PMC: 7677755. DOI: 10.1001/jamanetworkopen.2020.29256. View

3.
Yang S, Li Y, Dai L, Wang J, He P, Li C . Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21(8):1107-1119. PMC: 7990482. DOI: 10.1016/S1473-3099(21)00127-4. View

4.
Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

5.
Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V . Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021; 398(10317):2173-2184. PMC: 8584828. DOI: 10.1016/S0140-6736(21)02000-6. View